Lucy Godson

Lucy Godson

Auto-generated profile, based on publicly available information

Lucy Godson

National Pathology Imaging Cooperative, Leeds Teaching Hospitals NHS Trust, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Medical Image Analysis
Verified
Journal Article
Open access
LGLucy Godson
Lucy Godson
NANavid Alemi
Navid Alemi
Jérémie NsengimanaJérémie Nsengimana
Jérémie Nsengimana
GCGraham P. Cook
Graham P. Cook
ECEmily L. Clarke
Emily L. Clarke
DMDerek Magee
Derek Magee
Determining early-stage prognostic markers and stratifying patients for effective treatment are two key challenges for improving outcomes for melanoma patients. Previous studies have used tumour transcriptome data to stratify patients into immune subgroups, which were associated with differential melanoma specific survival and potential predictive biomarkers. However, acquiring transcriptome data is a time-consuming and costly process. Moreover, it is not routinely used in the current clinical workflow. Here, we attempt to overcome this by developing deep learning models to classify gigapixel haematoxylin and eosin (H&E) stained pathology slides, which are well established in clinical workflows, into these immune subgroups. We systematically assess six different multiple instance learning (MIL) frameworks, using five different image resolutions and three different feature extraction methods. We show that pathology-specific self-supervised models using 10x resolution patches generate superior representations for the classification of immune subtypes. In addition, in a primary melanoma dataset, we achieve a mean area under the receiver operating characteristic curve (AUC) of 0.80 for classifying histopathology images into 'high' or 'low immune' subgroups and a mean AUC of 0.82 in an independent TCGA melanoma dataset. Furthermore, we show that these models are able to stratify patients into 'high' and 'low immune' subgroups with significantly different melanoma specific survival outcomes (log rank test, P< 0.005). We anticipate that MIL methods will allow us to find new biomarkers of high importance, act as a tool for clinicians to infer the immune landscape of tumours and stratify patients, without needing to carry out additional expensive genetic tests.

11 May 2026 in Cancer Informatics
Verified
Journal Article
Open access
CJCharlotte Jennings
Charlotte Jennings
ABAndrew Broad
Andrew Broad
LGLucy Godson
Lucy Godson
ECEmily Clarke
Emily Clarke
DWDavid Westhead
David Westhead
DTDarren Treanor
Darren Treanor
This study systematically reviews and evaluates published research on machine learning models that integrate histopathology whole slide images and high-throughput -omic data to predict overall survival in cancer. A comprehensive search of PubMed, EMBASE, and Cochrane CENTRAL was conducted through August 12, 2024, with citation screening for additional studies. Eligible studies applied machine learning or deep learning methods to multimodal data combining pathology images and -omics. Data extraction followed the CHARMS checklist, and risk of bias was assessed using the PROBAST + AI tool. Narrative synthesis was conducted in line with PRISMA 2020 guidelines. Forty-eight studies published since 2017 met inclusion criteria, spanning 19 cancer types. All relied on The Cancer Genome Atlas dataset. Modelling approaches included regularised Cox regression (n = 4), classical machine learning (n = 13), and deep learning (n = 31). Reported concordance indices ranged from 0.550 to 0.857, with most multimodal models outperforming unimodal counterparts. However, all studies were assessed as having high or unclear risk of bias—most often due to limited external validation, insufficient reporting, and minimal assessment of clinical utility. This review highlights a rapidly evolving yet methodologically underdeveloped field. While model performance is promising, improvements in data standardisation, reporting practices, and real-world contextualisation are critical for clinical translation. This work was funded by the National Pathology Imaging Cooperative (NPIC), supported by UK Research and Innovation (Project no. 104687).

10 March 2024
Verified
Book Chapter
Closed access
PDF file
LGLucy Godson
Lucy Godson
NANavid Alemi
Navid Alemi
JNJérémie Nsengimana
Jérémie Nsengimana
GCGraham P. Cook
Graham P. Cook
ECEmily L. Clarke
Emily L. Clarke
DMDerek Magee
Derek Magee

26 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
GMGa Matthews
Ga Matthews
LGLucy Godson
Lucy Godson
CMClare McGenity
Clare McGenity
DBDaljeet Bansal
Daljeet Bansal
DTDarren Treanor
Darren Treanor
GMGillian A Matthews
Gillian A Matthews
B ackground: There is increasing momentum behind the clinical implementation of AI-based software for image analysis in digital pathology. As regulations, standards, and national approaches to the clinical use of AI continue to develop, the marketplace of AI products is expanding and evolving – presenting pathologists with a multitude of devices that offer the potential to improve pathology services. M ethods: To maintain pace with this changing AI device landscape, we conducted a comprehensive search for, and analysis of, commercial AI products for image analysis in digital pathology. This included CE-marked and Research Use Only (RUO) products using images with histological stains (e.g., H&E) or immunohistochemical (IHC) labelling. Product information and published clinical validation studies were assessed, to understand the quality of supporting evidence on available products, and product details were compiled into a public register: https://osf.io/gb84r/overview . R esults: In total, we identified and assessed 90 CE-marked and 227 RUO AI products. We found that AI products for cancer detection in prostate and breast pathology comprised a substantial portion of the marketplace for H&E image analysis, while IHC products were almost exclusively for use in breast cancer. Clinical validation studies on these products have steadily increased; however, we found that published studies were only available for just over half of H&E products and just over a quarter of IHC products. For CE-marked products, the dataset quality and diversity for AI model performance validation was highly variable, and particularly limited for IHC products. Furthermore, only a limited number of products included studies that assessed measures of clinical utility. C onclusion: As clinical deployment of AI products for image analysis in histopathology grows, there is a need for transparency, rigorous validation, and clear evidence supporting clinical utility and cost-effectiveness. Independent scrutiny of the expanding offering of AI products provides insight into the opportunities and shortcomings in this domain.